Finance

Beta
Lists
300601:SHE
Shenzhen Kangtai Biological Prods Co Ltd
CNÂ¥11.92
+0.85%
(+0.10) 1D
Jun 5, 3:04:52 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300601...
Open
CNÂ¥11.96
High
CNÂ¥12.08
Low
CNÂ¥11.85
Mkt. cap
13.31B
Avg. vol.
16.82M
Volume
9.51M
P/E ratio
170.87
52-wk high
CNÂ¥21.12
52-wk low
CNÂ¥11.79
EPS
CNÂ¥0.07
Shares outstanding
1.12B
No. of employees
2K
Open
CNÂ¥11.96
High
CNÂ¥12.08
Low
CNÂ¥11.85
Mkt. cap
13.31B
Avg. vol.
16.82M
Volume
9.51M
P/E ratio
170.87
52-wk high
CNÂ¥21.12
52-wk low
CNÂ¥11.79
EPS
CNÂ¥0.07
Shares outstanding
1.12B
No. of employees
2K
News stories
From sources across the web
Profile
Shenzhen Kangtai Biological Products, also known as BioKangtai, is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products. Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. Wikipedia
About Shenzhen Kangtai Biological Prods Co Ltd
CEO-
Employees1.96K
FoundedSep 8, 1992
Headquarters-
SectorBiotechnology
Websitebiokangtai.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
746.86M
671.38M
609.64M
631.11M
Cost of goods sold
258.02M
110.97M
267.74M
182.40M
Cost of revenue
258.02M
110.97M
267.74M
182.40M
Research and development expenses
176.30M
123.15M
123.35M
84.28M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
335.84M
291.37M
283.35M
302.79M
Operating expense
545.63M
425.29M
428.59M
406.24M
Total operating expenses
803.65M
536.26M
696.33M
588.65M
Operating income
-56.79M
135.12M
-86.69M
42.47M
Other non operating income
-258.41K
-375.71K
308.38K
-2.04M
EBT including unusual items
-27.09M
324.22K
45.26M
39.95M
EBT excluding unusual items
-64.69M
125.91M
-104.26M
19.66M
Income tax expense
-42.31M
-11.26M
24.17M
6.35M
Effective tax rate
156.17%
-3,472.08%
53.40%
15.89%
Other operating expenses
14.09M
3.89M
14.05M
6.96M
Net income
15.10M
11.62M
21.17M
33.34M
Net profit margin
2.02%
1.73%
3.47%
5.28%
Earnings per share
-
-
-
-
Interest and investment income
22.02M
20.88M
13.75M
8.72M
Interest expense
-29.25M
-30.13M
-30.16M
-29.50M
Net interest expenses
-7.23M
-9.24M
-16.42M
-20.77M
Depreciation and amortization charges
-
-
-
-
EBITDA
41.21M
212.79M
11.74M
140.90M
Gain or loss from assets sale
365.90K
-365.90K
934.47K
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer